

David C Cipolla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5159244/publications.pdf>

Version: 2024-02-01

64
papers

2,241
citations

218381

26
h-index

223531

46
g-index

65
all docs

65
docs citations

65
times ranked

2262
citing authors

#	ARTICLE	IF	CITATIONS
1	Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2022, 916, 174484.	1.7	4
2	Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 302.	2.0	12
3	Inhaled Medicines: Past, Present, and Future. <i>Pharmacological Reviews</i> , 2022, 74, 48-118.	7.1	44
4	Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 152, 106486.	1.0	11
5	Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 548.	1.8	9
6	Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 66, 101983.	1.1	4
7	Modeling of a spray drying method to produce ciprofloxacin nanocrystals inside the liposomes utilizing a response surface methodology: Box-Behnken experimental design. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120277.	2.6	31
8	Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0031621.	1.4	5
9	Recent advances in prodrug-based nanoparticle therapeutics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 219-243.	2.0	41
10	Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120809.	2.6	13
11	Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow ^Å ® Technology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 166, 10-18.	2.0	23
12	Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. <i>ERJ Open Research</i> , 2021, 7, 00592-2020.	1.1	8
13	Physical stability of dry powder inhaler formulations. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 77-96.	2.4	89
14	Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 Journal, 2020, 56, 2000110.	3.1	30
15	Nanoscale Probing of Liposome Encapsulating Drug Nanocrystal Using Atomic Force Microscopy-Infrared Spectroscopy. <i>Analytical Chemistry</i> , 2020, 92, 9922-9931.	3.2	12
16	Reflections on Digital Health Tools for Respiratory Applications. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 127-132.	0.7	7
17	Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 235-238.	0.7	27
18	Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119045.	2.6	18

#	ARTICLE	IF	CITATIONS
19	Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal) Tj ETQq1 1 0.784314 rgBT /Overlock		1
20	Comparison of Treprostinil Palmitil Inhalation Suspension (TPIS) or Oral Sildenafil (Sild) in a Sugen/Hypoxia Rat Model of PAH. , 2020, , .		0
21	Hemodynamic and histological progression in the Sugen-Hypoxia Rat Model. , 2020, , .		0
22	No evidence of desensitization to repeat dosing with treprostinil palmitil inhalation suspension (TPIS) for 32-consecutive days in hypoxia-challenged telemetered rats. , 2020, , .		0
23	Controlling the size and shape of liposomal ciprofloxacin nanocrystals by varying the lipid bilayer composition and drug to lipid ratio. Journal of Colloid and Interface Science, 2019, 555, 361-372.	5.0	13
24	Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection. Clinical Microbiology and Infection, 2019, 25, 1532-1538.	2.8	11
25	Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. International Journal of Pharmaceutics, 2019, 566, 641-651.	2.6	47
26	Direct Comparison of Standard Transmission Electron Microscopy and Cryogenic-TEM in Imaging Nanocrystals Inside Liposomes. Molecular Pharmaceutics, 2019, 16, 1775-1781.	2.3	18
27	Solid State Characterization of Ciprofloxacin Liposome Nanocrystals. Molecular Pharmaceutics, 2019, 16, 184-194.	2.3	12
28	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. Pharmaceutical Research, 2018, 35, 50.	1.7	11
29	Current and Emerging Inhaled Therapies of Repositioned Drugs. Advanced Drug Delivery Reviews, 2018, 133, 1-4.	6.6	7
30	Drug nanocrystallisation within liposomes. Journal of Controlled Release, 2018, 288, 96-110.	4.8	100
31	Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	25
32	Reduction of pulmonary exacerbations in two phase 3 Trials: in-depth analyses. , 2018, , .		1
33	Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA). , 2018, , .		1
34	Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB). , 2018, , .		2
35	Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections. , 2018, , .		1
36	Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 1-13.	0.7	23

#	ARTICLE	IF	CITATIONS
37	Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline. , 2017, , .		1
38	Development of Liposomal Ciprofloxacin to Treat Lung Infections. <i>Pharmaceutics</i> , 2016, 8, 6.	2.0	146
39	Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug. <i>Pharmaceutical Research</i> , 2016, 33, 2748-2762.	1.7	20
40	Will pulmonary drug delivery for systemic application ever fulfill its rich promise?. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1337-1340.	2.4	22
41	Formation of drug nanocrystals under nanoconfinement afforded by liposomes. <i>RSC Advances</i> , 2016, 6, 6223-6233.	1.7	38
42	Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 411-422.	0.7	23
43	Comment on: Inhaled antimicrobial therapyâ€™Barriers to effective treatment, by J. Weers, <i>Inhaled antimicrobial therapy â€™ Barriers to effective treatment</i> , <i>Adv. Drug Deliv. Rev.</i> (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013 . <i>Advanced Drug Delivery Reviews</i> , 2015, 85, e6-e7.	6.6	5
44	Inhaled nicotine replacement therapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 472-480.	4.3	15
45	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 83-89.	2.0	46
46	Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 314-327.	1.6	49
47	Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 53-80.	6.6	107
48	Modifying the Release Properties of Liposomes Toward Personalized Medicine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1851-1862.	1.6	49
49	Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. <i>AAPS PharmSciTech</i> , 2014, 15, 1218-1227.	1.5	17
50	Liposomal formulations for inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1047-1072.	1.2	120
51	Inhaled antibiotics to treat lung infection. <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 647-663.	0.4	44
52	Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. <i>Thorax</i> , 2013, 68, 812-817.	2.7	221
53	Equivalence Considerations for Orally Inhaled Products for Local Actionâ€™ISAM/IPAC-RS European Workshop Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 117-139.	0.7	54
54	Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. <i>Pharmaceutical Research</i> , 2012, 29, 3335-3346.	1.7	75

#	ARTICLE	IF	CITATIONS
55	Formulation technology to repurpose drugs for inhalation delivery. Drug Discovery Today: Therapeutic Strategies, 2011, 8, 123-130.	0.5	41
56	Safety, Tolerability And Pharmacokinetics Of Novel Liposomal Ciprofloxacin Formulations For Inhalation In Healthy Volunteers And Non-Cystic Bronchiectasis Patients. , 2010, , .		5
57	Personalizing aerosol medicine: development of delivery systems tailored to the individual. Therapeutic Delivery, 2010, 1, 667-682.	1.2	30
58	Pulmonary Formulations: What Remains to be Done?. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, S-5-S-23.	0.7	91
59	Minimizing Variability of Cascade Impaction Measurements in Inhalers and Nebulizers. AAPS PharmSciTech, 2008, 9, 404-413.	1.5	54
60	AERx®Pulmonary Drug Delivery Systems. , 2008, , 563-571.		3
61	Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Advanced Drug Delivery Reviews, 2007, 59, 444-453.	6.6	190
62	Aerosolized Protein Delivery in Asthma: Gamma Camera Analysis of Regional Deposition and Perfusion. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2001, 14, 185-195.	1.2	53
63	Investigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharmaceutical Research, 1999, 16, 808-812.	1.7	26
64	Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. Pharmaceutical Research, 1994, 11, 491-498.	1.7	35